Suppliers / Chongqing Mideco Pharmaceutical

Chongqing Mideco Pharmaceutical

China Updated 9 July 2026

Chongqing Mideco Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files and one valid CEP across a filed portfolio of 4 molecules.

3
active US DMFs
1
valid CEPs
1
registered plants
0
filings across 0 regulators

Registered plants

Site FDA FEI
Jinfeng Town, China Not on file

What they file, and where

Molecule Regulators Docs
Carfilzomib US FDA 1
Ixazomib US FDA 1
Sapropterin US FDA 1
Zinc EDQM 1

Also appears on these molecule pages

Questions about Chongqing Mideco Pharmaceutical

Does Chongqing Mideco Pharmaceutical hold a US DMF or a CEP?
Chongqing Mideco Pharmaceutical holds 3 active US drug master files and 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Where does Chongqing Mideco Pharmaceutical manufacture?
1 registered site is on record, in China (Jinfeng Town). Every site is listed on this page with the register it came from.
What does Chongqing Mideco Pharmaceutical make?
4 molecules are on record against Chongqing Mideco Pharmaceutical, including Carfilzomib, Ixazomib, Sapropterin and Zinc. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Chongqing Mideco Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability